<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3973">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361474</url>
  </required_header>
  <id_info>
    <org_study_id>MDL_2020_10</org_study_id>
    <nct_id>NCT04361474</nct_id>
  </id_info>
  <brief_title>Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity</brief_title>
  <acronym>COVIDORL</acronym>
  <official_title>A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hopital Lariboisière</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The initial symptoms described in the first cases of COVID-19 were mainly fever and&#xD;
      respiratory signs. Recently, there has been an increase in cases of hyposmia without&#xD;
      associated nasal obstruction or rhinorrhea. Although we do not yet know the long-term&#xD;
      consequences of COVID-19 on olfaction, there is evidence in the literature demonstrating that&#xD;
      post-viral hyposmias are an important source of long-term olfactory disorders, impacting&#xD;
      quality of life.&#xD;
&#xD;
      Usually, the treatment of viral hyposmias is based on local and/or general corticosteroid&#xD;
      treatment combined with saline nasal irrigation at the onset of signs. Because of the&#xD;
      possible development of severe forms of the SARS-Cov-2 infection, the French Society of&#xD;
      Otorhinolaryngology has advised against treatment by corticosteroid therapy and nasal&#xD;
      irrigation. However, as the virus is present in the nasal fossae on average for 20 days,&#xD;
      persistent hyposmia at 30 days would probably result from an inflammatory or neurological&#xD;
      damage to the nasal slits or olfactory bulb. Local treatment with corticosteroids could then&#xD;
      be instituted from 30 days after the onset of symptoms of COVID-19 without risk of&#xD;
      dissemination.&#xD;
&#xD;
      In persistent hyposmia other than chronic rhinosinusitis, the only treatment that has proven&#xD;
      its efficacy is nasal irrigation associated with budesonide and olfactory rehabilitation.&#xD;
      However, this drug does not have marketing authorisation in France for this indication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter randomized trial to evaluate the efficacy of local budesonide (nasal&#xD;
      irrigation) in the management of persistent hyposmia in COVID-19 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">May 25, 2021</completion_date>
  <primary_completion_date type="Actual">November 24, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with persistent hyposmia related to a SARS-CoV-2 infection</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients with persistent hyposmia related to a SARS-CoV-2 infection</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Patient with more than 2 points on the ODORATEST</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of patients with an improvement of more than 2 points on the ODORATEST score (5) after 30 days of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Budesonide</condition>
  <condition>Olfaction Disorders</condition>
  <condition>SARS-CoV-2</condition>
  <condition>Anosmia</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal irrigation with budesonide and physiological saline (Budesonide 1mg/2mL diluted in 250mL of physiological saline 9°/00): 3 syringes of 20mL in each nasal cavity, morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nasal irrigation with physiological saline 9°/00 only: 3 syringes of 20cc in each nasal cavity, morning and evening, for 30 days, in addition to olfactory re-education twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide Nasal</intervention_name>
    <description>Nasal irrigation with budesonide and physiological saline morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Experimental group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physiological serum</intervention_name>
    <description>Nasal irrigation with physiological saline morning and evening, for 30 days, in addition to olfactory re-education twice a day.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years of age;&#xD;
&#xD;
          -  Patient with a suspected SARS-CoV-2 infection in a epidemic context, whether or not&#xD;
             confirmed by PCR, or contact close to a PCR-confirmed case, typical chest CT scan&#xD;
             (unsystematized frosted glass areas predominantly sub-pleural, and at a later stage of&#xD;
             alveolar condensation with no excavations neither nodules nor masses) or positive&#xD;
             serology ;&#xD;
&#xD;
          -  Patient with isolated acute hyposmia persisting at D30. of the onset of signs of&#xD;
             CA-MRSA-CoV-2 infection;&#xD;
&#xD;
          -  Absence of PCR-confirmed SARS-CoV-2 portage at the time of inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to budesonide or to any of the excipients of the medicine;&#xD;
&#xD;
          -  Hemostasis disorder, or epistaxis;&#xD;
&#xD;
          -  Oromo-oral-nasal and ophthalmic herpes virus infection;&#xD;
&#xD;
          -  Long-term corticosteroid treatment;&#xD;
&#xD;
          -  Treatment with potent CYP3A4 inhibitors (e.g., CYP3A4 inhibitors); ketoconazole,&#xD;
             itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone&#xD;
             and HIV proteases) ;&#xD;
&#xD;
          -  Forms of CoV-2-SARS with respiratory signs or other than anosmia persisting at 30 days&#xD;
             from the onset of symptoms;&#xD;
&#xD;
          -  Hyposmia persisting for more than 90 days after onset of symptoms;&#xD;
&#xD;
          -  Other causes of hyposmia revealed on interrogation or an MRI;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary DAVAL</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Fondation A de Rothschild</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amélie YAvchitz</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olfaction Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

